Time to early death, time from progression to death, and time to thromboembolic event. (A) Time to early death (within 12 months after entry into the trial) due to all causes or due to non–myeloma-related causes by treatment. (B) Time from progression to death by treatment. (C) Time to thromboembolic event b treatment.